Immunotherapy combo shows promise in hodgkin lymphoma trial

NCT ID NCT07234487

First seen Nov 18, 2025 · Last updated Jun 04, 2026 · Updated 20 times

Summary

This study compares two first-line treatments for advanced Hodgkin lymphoma. One group gets a new combination of the immunotherapy drug nivolumab plus chemotherapy (AVD), while the other group receives standard chemotherapy (BEACOPP-like). The goal is to see which approach is safer and more effective. About 178 adults aged 18-60 with newly diagnosed stage IIB, III, or IV Hodgkin lymphoma will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • A.N.Bakulev Center for cardiovascular surgery of the Russian Ministry of Health

    RECRUITING

    Moscow, Russia

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • National Medical and Surgical Center named after N.I. Pirogov

    RECRUITING

    Moscow, Russia

    Contact Email: •••••@•••••

  • St. Petersburg State Pavlov Medical University

    RECRUITING

    Saint Petersburg, Russia

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.